Imunon, Inc. Files 8-K: Procedural Update

Ticker: IMNN · Form: 8-K · Filed: Aug 1, 2024 · CIK: 749647

Imunon, INC. 8-K Filing Summary
FieldDetail
CompanyImunon, INC. (IMNN)
Form Type8-K
Filed DateAug 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, procedural

Related Tickers: IMNN

TL;DR

IMNN filed an 8-K, looks like a routine update, no big news.

AI Summary

Imunon, Inc. filed an 8-K on August 1, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about new events, financial figures, or material changes, but rather serves as a procedural update.

Why It Matters

This filing indicates a routine update from Imunon, Inc. to the SEC, suggesting no immediate material events or changes to report at this time.

Risk Assessment

Risk Level: low — The filing is a standard procedural update with no new material information, indicating low immediate risk.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing?

The filing reports "Other Events" and "Financial Statements and Exhibits" as items of disclosure, but does not provide specific details on new events within the provided text.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on August 1, 2024.

What is the state of incorporation for Imunon, Inc.?

Imunon, Inc. is incorporated in Delaware.

What is the principal executive office address for Imunon, Inc.?

The principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311.

Does this 8-K filing contain specific financial figures or material updates?

Based on the provided text, this 8-K filing appears to be a procedural update and does not contain specific financial figures or details of material changes.

Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-01 08:38:30

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Dated: August 1, 2024 By: /s/ David Gaiero David Gaiero Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing